NDA 020918 · Novo Nordisk
Glucagen
Glucagon Hydrochloride · Intramuscular, Intravenous, Intramuscular, Intravenous, Subcutaneous
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jun 22, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,156
249 Phase 3, 174 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- GLUCAGEN · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR, INTRAVENOUS · Discontinued
- GLUCAGEN · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.
- High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention ProgramPivotal-lookingStatus unknown
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05782881 · 16,000 participants (planned) · Start Jan 15, 2023 · Primary completion Dec 31, 2023
Drug: Statin · For: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Coronary Disease
Sites: Enshi, China; Ezhou, China; Huanggang, China · 107 sites in all
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02465515 · 9,463 participants · Start Jul 1, 2015 · Primary completion Feb 20, 2018
Drug: Albiglutide 30 mg; Albiglutide 50 mg and 1 more · For: Diabetes Mellitus
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 607 sites in all
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01179048 · 9,341 participants · Start Aug 31, 2010 · Primary completion Dec 17, 2015
Drug: liraglutide; placebo · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 428 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Glucagen (Glucagon)
2024 spending
$3.5M
Beneficiaries
6,698
9,424 claims
Per beneficiary
$526
$315.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,155,989 |
| 2021 | $8,610,124 |
| 2022 | $5,888,486 |
| 2023 | $4,903,701 |
| 2024 | $3,521,871 |
Part B: Glucagen* (Glucagon*) · HCPCS J1610
2024 spending
$4.8M
Beneficiaries
21,431
22,838 claims
Per beneficiary
$222
2024 ASP limit $190.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,481,071 |
| 2021 | $8,005,095 |
| 2022 | $7,391,309 |
| 2023 | $5,792,255 |
| 2024 | $4,763,004 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.
Chiang CH, Jaroenlapnopparat A, Colak SC, et al. · Gastroenterology 2025 · Systematic Review, Meta-Analysis
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
Berg S, Stickle H, Rose SJ, et al. · Obes Rev 2025 · Meta-Analysis, Systematic Review
- The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
Liu Y, Ruan B, Jiang H, et al. · Am J Clin Nutr 2023 · Meta-Analysis, Systematic Review
- Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.
Esparham A, Mehri A, Dalili A, et al. · Obes Rev 2024 · Meta-Analysis, Systematic Review
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.
Radkhah H, Rahimipour Anaraki S, Parhizkar Roudsari P, et al. · Eat Weight Disord 2025 · Systematic Review, Meta-Analysis
- Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Silverii GA, Monami M, Gallo M, et al. · Diabetes Obes Metab 2024 · Meta-Analysis, Systematic Review
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.